NorthWest Biotherapeutics Inc (NWBO)

[abeta]

March 2nd 2024
https://www.ft.com/content/4fe0f032-07e5-41d7-ac85-cceb252129a3

But the default stance adopted by market-makers — who claim allegations of market manipulation are implausible while declining to divulge the commercially sensitive intricacies of their high-tech platforms — has now been effectively knocked back.

Stein wrote that the fact NWBO did not specify what algorithmic trading programmes were used by defendants to execute their schemes or how they were used was not an impediment to its case. “It is hard to imagine how any spoofing case would survive the motion to dismiss stage if?.?.?.?‘facts solely within the defendant’s knowledge,’ were required to be set forth in the complaint”, he added. In other words, if Citadel Securities and its ilk are to beat this case and prevent a string of copycat suits, they will probably have to give the rest of us more of a peek behind the curtain.